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ABSTRACT 
Background: EQ-5D data on patients’ health-related quality of life (HRQoL) are collected 
in roughly 40% of about 100 National Quality Registers (NQRs) in Sweden. The aim of the 
thesis was to increase knowledge on the use of the EQ-5D-3L in assessing HRQoL of 
patients in different NQRs and to compare different value sets used to describe HRQoL. 
Methods: In Study I, data on patients from 11 NQRs with spine surgery, hip arthroplasty, 
knee arthroplasty, ankle surgery, anterior cruciate ligament, osteoarthritis, fractures, heart 
failure, respiratory failure, psoriasis, and rheumatology were included. A total of 266,241 
patients from the NQRs and 49,169 members of the general population were included. In 
Study II, 69,290 patients in the Swedish Hip Arthroplasty Register at baseline and 1-year 
follow-up, and 21,305 patients at 6-year follow-up were included. Data on demographic 
and clinical characteristics and EQ-5D-3L data were retrieved in both studies. In Study I, 
descriptive analyses, Paretian Classification of Health Change (PCHC) and a two-level 
random intercept model of the impact of diagnoses on EQ VAS scores were performed. 
EQ-5D-3L indices were calculated using eight value sets from Sweden, Germany, 
Denmark, and the UK. One-way analysis of variance was used to assess the discriminative 
ability of the value sets across American Society of Anaesthesiologists (ASA) classes.  
Results: In Study I, the pain/discomfort dimension was the dimension with the highest 
proportion of problems reported both in most registers and in the general population. The 
highest proportion of improved category of PCHC were reported by patients from the 
ankle, hip, knee, and spine registers. The two-level random intercept models of EQ VAS 
score, as predicted by diagnoses, showed patients in most registers, with the exception of 
fractures, had lower scores than the general population at baseline and at 1-year follow-up. 
In Study II, all value sets were able to discriminate HRQoL among the ASA classes, and 
showed the predictive ability of ASA classes on HRQoL.  
Conclusion: Both studies demonstrated the importance of the EQ-5D-3L instrument in 
providing HRQoL data to complement clinical data. The studies documented HRQoL of 
different patient groups and demonstrated the consistency of the EQ-5D-3L dimensions and 
the EQ VAS score. All the value sets used to summarize EQ-5D-3L data showed that ASA 
classes predicted HRQoL and demonstrated ability to differentiate across ASA classes. 
Key words: American Society of Anesthesiologists (ASA) physical status classification 
system, EQ-5D, EQ-5D-3L, EQ VAS, Health-Related Quality of Life (HRQoL), National 
Quality Register (NQR), Sweden 
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1. BACKGROUND 
1.1. PATIENT-REPORTED OUTCOMES   
Patient-reported outcomes (PROs) provide important insight into outcomes that matter the 
most to patients. So, their incorporation in clinical trials as well as routine care helps to 
address views of patients [1]. PROs are described by the United States Food and Drug 
Administration as information on the health status of patients received from them directly, 
without interpretation by physicians or others [2]. PROs provide information on patients’ 
perspective on their health condition, not available from other sources [3]. Several benefits of 
PROs have been described at both individual and population levels. At an individual level, 
PROs are helpful in informing clinical decisions, in consultation with patients, and focusing 
on the needs of patients in clinical care. They are also useful in prioritizing resource 
allocation for patients who need them most [4]. PROs have also been used in screening for 
diseases as well as tracking progress made by patients [5]. At population level, PROs can 
inform activities to improve the quality of clinical care provided to patients and in planning 
treatment [4]. PROs data can also be employed to compare quality of care across various 
health care providers [6]. Routine collection of data on PROs in registries is also associated 
with important functions, including assessment of the natural history of diseases and the 
effectiveness of treatments, as well as in the assessment of quality of care [7]. 
1.2. HEALTH-RELATED QUALITY OF LIFE  
Health-related quality of life (HRQoL) has been defined in many ways with no universally 
accepted definition. However, definitions of HRQoL are described as having two common 
aspects: multidimensionality and the inclusion of objective and subjective perspectives [8]. 
Karimi and Brazier (2016) identified four definitions of HRQoL in the literature, including 
“how well a person functions in their life and his or her perceived wellbeing in physical, 
mental and social domains of health” [9–11]. Another definition describes quality of life as a 
broad concept concerning various factors that affect an individual’s life. Hence, HRQoL is 
described as a concept focused on the factors related to an individual’s health [10,12]. A third 
definition describes HRQoL as “those aspects of self-perceived wellbeing that are related to 
or affected by the presence of disease or treatment”. The fourth definition describes HRQoL 
as the values or utilities of different health states [10,13].  
HRQoL instruments are categorized as generic or condition-specific. Generic measures are 
employed to capture the physical, psychological, and social components of health defined by 
the World Health Organization [14]. They can be employed in any population to measure 
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HRQoL and to compare the burden of diseases across different patient groups [9,15]. Generic 
measures are useful in clinical and research applications. Clinically, generic measures provide 
information on the impact of treatments on the health and quality of life of patients. In this 
way the measures provide information complementary to other clinical data. In research, 
generic measures complement data from clinical trials by incorporating patients’ perspectives 
on their health. They can also be used in studies on cost-effectiveness of treatments [14]. The 
most commonly used generic HRQoL measures include EQ-5D and the 36-item Short-Form 
Health Survey (SF-36), among others. Condition-specific instruments are used to measure 
changes in dimensions of relevance for specific conditions. They are developed to detect 
small treatment changes in a manner more sensitive than generic measures. There are 
numerous condition-specific HRQoL measures available for different diseases [16]. 
Data on HRQoL are applied in resource allocation as they play a role in the calculation of 
quality-adjusted life years (QALYs). QALYs is a single measure combining the impact of 
interventions on survival (life years gained) and on HRQoL over this duration [17]. QALYs 
are used as outcome measures in economic evaluations, mainly cost-utility analyses where 
costs and outcomes in the form of QALYs are compared among alternative interventions 
aiding resource allocation decisions [18].  
1.3. EQ-5D 
EQ-5D is a brief generic HRQoL instrument widely used to describe and value health across 
different disease areas. It covers physical, emotional, and social functioning aspects presented 
in a five-dimension questionnaire [19,20]. The five dimensions, mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression, form the descriptive system. The visual 
analogue scale (EQ VAS), in which respondents report their overall health status, forms a 
second component of the EQ-5D questionnaire. It is a vertical line ranging from zero, 
labelled ‘worst imaginable health state’, to 100, ‘best imaginable health state’ [19,20]. There 
are four versions of the EQ-5D, namely EQ-5D-3L, EQ-5D-5L, EQ-5D-Y-3L, and EQ-5D-
Y-5L [21–24]. The EQ-5D-3L version has three severity levels in its descriptive system. 
These are no problems, some/moderate problems, and confined to bed/unable to/extreme 
problems. A self-reported version of EQ-5D-3L is available in more than 180 languages 
worldwide [21]. The descriptive system of the EQ-5D-5L has five levels of severity: no 
problems, slight problems, moderate problems, severe problems, and unable to/extreme 
problems. It has been introduced to improve the sensitivity of the EQ-5D-3L [19]. The EQ-
5D-Y (EQ-5D-Y-3L) is a version of the EQ-5D-3L questionnaire, used among children and 
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adolescents. The self-completed version is available in over 90 languages [23]. A five-level 
severity version of the EQ-5D-Y (EQ-5D-Y-5L) has been developed recently [24]. 
A health state summarizes the health status of a respondent based on the level of severity of 
problems reported on the five dimensions in the EQ-5D descriptive system. For example, a 
person who reported some problems regarding mobility, no problems with self-care, some 
problems with usual activities, extreme problems regarding pain/discomfort, and moderate 
problems in the anxiety/depression dimensions is said to have a health state of 21232. 
Presented in this manner, a total of 243 unique health states are possible [21].  
1.3.1. EQ-5D-3L VALUE SETS  
The health status of respondents described as a health state can be summarized into a single 
EQ-5D-3L index, incorporating the weights provided to the severity level. A set of such 
weights is known as value sets. Value sets are formulas developed to transform health states 
into an EQ-5D-3L index, by attaching specific weights to the different severity levels [21]. 
EQ-5D-3L value sets are developed by valuation studies in the general population using 
health state valuation methods such as time trade-off (TTO) and the visual analogue scale 
(VAS). Thus far, more than 30 countries have developed EQ-5D-3L value sets. TTO method 
of valuation has been employed in most of these value sets [21].  
In the TTO valuation, respondents are asked to compare living for a specific period of time 
with a certain health state to living for shorter duration in full health [25]. The TTO question 
can be presented through iterative comparisons with shorter durations. The point at which a 
respondent becomes indifferent between the compared states signifies the value a respondent 
assigns to the health state in question [26]. Another approach to presenting a TTO question 
involves a horizontal line marked with duration of time for which respondents indicate the 
duration at which they are indifferent between living in a specific health state for 10 years, 
versus in full health. This method has been used in different studies where respondents valued 
their own health through the TTO method [27–29].  
In the VAS valuation method, the EQ-5D VAS is employed for valuation of a list of specified 
EQ-5D health states. This provides the stated preference of respondents for a specified health 
states by using the 0 (‘worst imaginable health state’) to 100 (‘best imaginable health state’) 
range [30]. The EQ VAS, on the other hand, is used by individuals to report on their own 
health state. However, EQ VAS has also been used to develop value sets in several studies 
where respondents value their own health states [27,28,31–36]. In economic evaluations, the 
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use of different value sets has been shown to impact the calculation of QALYs in different 
studies, leading to different outcomes in various economic evaluation studies [37–39]. 
1.3.2. PERSPECTIVES IN VALUATION  
Hypothetical perspectives of the general public are commonly employed in valuation 
exercises conducted to develop value sets. In these valuations, respondents are presented with 
specified health states to value [40,41]. Experience-based health state valuation involves 
respondents valuing their own health state [42,43]. This perspective has been applied in 
different studies involving health state valuations [27,29]. Most of the EQ-5D-3L value sets 
developed so far have employed hypothetical perspectives [21]. However, there is an 
increasing discussion about and interest in experience-based value sets [40]. Accordingly, 
several country level value sets have been developed using this perspective as well 
[27,28,31–33]. There are discussions on the use of hypothetical or experience-based 
perspectives [44]. Hypothetical and or experience-based perspectives have been shown to 
lead to different values, making the choice of perspective to consider an important issue to 
discuss [45].  
Different recommendations have been made regarding the choice of valuation perspective 
when the value sets are aimed to be used for the purposes of economic evaluation. For 
instance, in Sweden the Dental and Pharmaceutical Benefits Agency recommends the use of 
experience-based perspective in its guidelines from 2003 and in the updated version in 2017 
[46,47]. However, in the UK valuation studies among the general population using 
hypothetical perspectives are recommended for value sets developed to calculate QALYs for 
economic evaluation [48].  
1.4. NATIONAL QUALITY REGISTERS IN SWEDEN 
In Sweden, there are about 100 National Quality Registers (NQRs) which collect data on 
patients’ diagnoses, treatments, and outcomes [49]. These individual-based data are collected 
and used to improve quality of health care, to monitor compliance with guidelines and for 
research. The clinical benefits of making use of the data from the NQRs have been 
established in different clinical areas, showing improvements in health care [50]. In more 
than 40% of the NQRs, PROs are also collected using the EQ-5D [50].  
Most of the NQRs in Sweden were initiated by health professionals. The first NQR dates 
back to 1975, with the initiation of the Swedish Knee Arthroplasty Register (SKAR). Most of 
the NQRs had a completeness rate of higher than 80% in 2020 [51]. Furthermore, the NQRs 
employ validation approaches on the data collected in the registers [50].  
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1.5. RATIONALE  
Studies comparing HRQoL of different patient groups at time points in a comprehensive 
manner are not common. So, the present thesis helps to fill this gap in the literature. It has 
been conducted to provide information on the HRQoL of patients in different NQRs in 
different clinical stages and time points in a manner that reflects the viewpoint of patients 
regarding their condition, complementing objective clinical information.  
There is also research gap regarding the use of different EQ-5D-3L value sets in in 
summarizing data on HRQoL into an EQ-5D-3L index. Data on HRQoL collected using EQ-
5D-3L are commonly presented using value sets chosen from the several EQ-5D-3L value 
sets available. Value sets could vary based on the method of valuation used and perspective 
taken, as well as other factors, such as study setting and modelling approaches used. In 
addition, the extent to which the use of different value sets shows the discriminative abilities 
of clinical variables categorizing patients into different groups and their predictive abilities 
remains to be studied. Among such classifications is the American Society of 
Anaesthesiologists physical status classification system (ASA). It provides a way to make a 
simple categorization of patients undergoing surgery to determine their operative risk [52].  
So, comparison of how using different value sets to summarize HRQoL affects the resulting 
indices and choices made based on them is important. This has implications on how the 
discriminative and predictive abilities of ASA classes are shown when using different EQ-
5D-3L value sets. Hence, the present thesis was conducted to assess this through making the 
comparisons across EQ-5D-3L value sets.  
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2. AIM  
The overall aim of the thesis was, using longitudinal studies, to increase knowledge on the 
use of the EQ-5D-3L in assessing the HRQoL of patients in different National Quality 
Registers (NQRs) in Sweden, and to compare different value sets from four countries in 
Europe employed to describe HRQoL. 
The specific objectives were:  
 To compare problems reported in the five EQ-5D-3L dimensions and EQ VAS scores at 
baseline and at 1-year follow-up among different patient groups and specific diagnoses in 
11 NQRs, and to compare with data from the general population (Study I). 
 To compare the discriminative abilities of EQ-5D-3L value sets from Sweden, Germany, 
Denmark, and the UK in relation to the American Society of Anaesthesiologists physical 
status classification system (ASA) classes, and to compare the predictive ability of ASA 
class on HRQoL using these value sets based on data from patients who underwent total 
hip replacement (THR) in Sweden (Study II). 
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3. METHODS 
3.1. NATIONAL QUALITY REGISTERS IN THE THESIS   
A total of 11 NQRs were included in the present thesis. All were employed in Study I, as the 
aim was to assess the HRQoL of patients from different NQRs at different time points and 
compare this with the general population. The registers spanned over a variety of disease 
groups, ranging from those focused mainly on diseases and interventions in the 
musculoskeletal system, to those focused on others such as heart failure, rheumatology, 
psoriasis, and respiratory failure. General information on the registers, including year of 
establishment, diseases areas and interventions covered, enrollment in terms of number of 
patients, and timeline for EQ-5D data collection are provided in Table 1. The Swedish Hip 
Arthroplasty Register (SHAR) was used in study II.  
3.2. GENERAL POPULATION DATA   
In Study I, HRQoL data from the 11 registers were compared with data from the general 
population in Sweden. This was a survey employed in the development of the experience-
based Swedish EQ-5D-3L TTO and VAS value sets [27].  
3.3. PARTICIPANTS    
A large number of participants were included in both studies, owing to the rich data provided 
in the Swedish NQRs which have a high completion rate. In Study I, a total of 266,241 
patient records from the 11 NQRs with complete data at baseline and at 1-year follow-up, as 
well as 49,169 from the general population were included. In Study II, 69,290 patient records 
from the SHAR with complete data at baseline and at 1-year follow-up, and 21,305 records at 
6-year follow-up were used.  
3.4. STUDY DESIGN  
In order to assess HRQoL at baseline and at follow-up stages as well as the changes in 
between a longitudinal study design was employed in both studies. Accordingly, the HRQoL 
of patients was assessed at baseline and at 1-year follow-up in both studies. In addition, 
assessment of the 6-year follow-up was performed in Study II.   
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Table 1: General information and EQ-5D data collection in the 11 National Quality Registers included in this project [50,53] 
Register Diagnosis/ condition Interventiona  Start 
year 
Unique 
patientsb 
New entries 
per yearb 
Follow-up times for EQ-5D 
Intervention-based 
registers 
Swedish Spine Register 
(Swespine) 
Spinal stenosis, disk hernia, 
and other spinal diagnoses 
Spine surgery  1993 130,000 10,000 Before surgery, 1, 2, 5, and 10 years 
after 
Swedish Hip Arthroplasty 
Register (SHAR) 
Hip osteoarthritis and other 
hip joint diagnoses  
Hip replacement 1979 370,000 25,000 Before surgery, 1, 6 and 10 years 
after 
Swedish Knee Arthroplasty 
Register (SKAR) 
Knee osteoarthritis and 
other knee joint diagnoses 
Knee replacement 1975 220,000 16,000 Before surgery, 1-year after  
 
Swedish Ankle Registry 
(Swedankle) 
Osteoarthritis and 
inflammatory conditions in 
the ankle  
Total ankle arthroplasty, 
ankle arthrodesis 
procedures 
1997 4,000 400 Before surgery, 6 months, 1 and 2 
years after 
Swedish National Anterior 
Cruciate Ligament Register 
(XBase) 
Cruciate ligament injuries Cruciate ligament 
surgery  
2005 46,000 4,000 Before surgery, 1, 2, 5 and 10 years 
after 
Better management of 
patients with osteoarthritis 
(BOA) 
Hip, knee, hand 
osteoarthritis  
Supported Osteoarthritis 
Self-Management 
Programme (SOASP) 
2008 110,000 18,000 First visit, 3 and 12 months; 1, 2, 3, 
4, 5, 6, and 7 years after  
(100 patients per year are 
randomized to continued follow-ups) 
Swedish Fracture Register 
(SFR) 
All types of fractures 
including vertebral/ spinal 
fractures 
Surgical and non-
surgical treatments  
2011 430,000 82,000 A week before injury (recall) and 1-
year after 
Diagnosis-based 
registers 
Swedish Heart Failure 
Registry (SwedeHF) 
Chronic heart failure Pharmacological 
treatment, physical 
activity 
2003 92,000 9,500 At new visit, within 6 months and 1-
year, once every year 
 
Swedish National Register 
for Respiratory Failure 
(Swedevox) 
Long-term oxygen therapy 
(LTOT) due to respiratory 
failure 
LTOT 1987 20,000 1,200 At treatment start, 1-year after 
 
Swedish Registry for 
Systematic Psoriasis 
Treatment (PsoReg) 
Psoriasis Systemic treatment for 
psoriasis 
2007 6,500 500 At each revisit due to psoriasis/ visit 
to the skin clinic/ telephone 
conversation with a dermatologist  
Swedish Rheumatology 
Quality Register (SRQ) 
Rheumatic diseases Medical treatment, 
rehabilitation 
1995 80,000 7,000 At visit  
 
a In this research project, unless stated otherwise, the term intervention refers to procedures such as surgeries or other forms of treatments provided to patients in the registers. 
b Information on the number of unique patients and new entries per year was gathered through communication with the respective registers.
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3.5. DATA  
In the present thesis, demographic, clinical and PROs data were retrieved from the registers 
and general population data. In Study I, data on age, sex, height, and weight (body mass 
index (BMI)), the EQ-5D-3L dimensions, and EQ VAS were retrieved from the 11 registers 
and data on the general population. Furthermore, data on diagnosis and interventions were 
retrieved from the registers. The data collected spanned the period from 2001 to 2019.  
In Study II, a similar set of data components were retrieved from the SHAR. In addition, data 
on the laterality of the arthroplasty (right or left side), ASA class of patients, as well as 
Charnley class were retrieved in Study II. As the study focused on the relationship between 
ASA class and HRQoL, the data retrieved and included in the study are from the years 2008 
(when collection of data on ASA class was initiated in the SHAR) to 2016 [54].  
3.6. AMERICAN SOCIETY OF ANESTHESIOLOGISTS PHYSICAL 
STATUS CLASSIFICATION SYSTEM  
In Study II, the predictive effect of ASA class on HRQoL at baseline, and at 1-year and 6-
year follow-ups was assessed. The ASA classification system was introduced in 1941 to 
assess the operative risk of patients prior to surgery [52]. After various updates at different 
times, ASA class currently categorizes patients preoperatively into six groups based on their 
operative risk [55]. A person in ASA class I is described as a normal healthy patient, for 
example a patient that is healthy and non-smoking, with no or minimal use of alcohol. 
Patients categorized in ASA class II are those with mild systemic disease. Such patients are 
described as not having considerable functional limitations. A patient with severe systemic 
disease is categorized in ASA class III. Such patients have considerable functional 
limitations. Patients in ASA class IV are those with severe systemic disease, which presents a 
constant threat to life. Examples of such patients are those with ongoing cardiac ischemia or 
recent myocardial infarction. Patients categorized in ASA class V are patients in a state in 
which they are not expected to survive without an operation, for example a patient 
experiencing massive trauma. Patients that are declared brain dead are categorized in ASA 
class VI [55]. In Study II, records of patients categorized in ASA class I to IV were included.  
3.7. VALUE SETS EMPLOYED IN THE THESIS 
In Study II, eight EQ-5D-3L value sets were compared to assess their ability to discriminate 
across ASA classes and show the predictive effect of ASA class on HRQoL. Four of the 
value sets were developed using the TTO method, and the remaining four were developed 
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through the VAS method. The value sets are, TTO and VAS from Sweden [27], Germany 
[32,56], Denmark [41,57], and the UK [41,58].  
3.7.1. TIME TRADE-OFF VALUE SETS   
Among the TTO value sets used in Study II, the value set from Sweden was developed 
through an experience-based approach in a study of more than 45,000 participants from the 
general population in which they valued their own health states. In the study, a total of 148 
health states were valued by the participants [27]. The remaining three TTO value sets from 
Germany, Denmark, and the UK were all developed through a hypothetical perspective, in 
which participants valued specific health states [56–58]. In the development of the German 
value set, a study conducted between 1978 and 1998 in northern Germany was used. In the 
study, 339 participants valued 15 health states each, selected from a total of 36 health states 
[56]. The value set from Denmark comes from a study conducted in 2000, involving 1,332 
participants from the general population. A total of 46 health states were valued, with 16 
health states presented to each respondent [57]. The UK EQ-5D-3L TTO value set was 
developed based on a survey with 3,395 respondents among the general population in the 
UK. A total of 42 health states were valued, with 13 health states valued by each respondent 
[58]. The TTO valuation approach employed in this study was also used in the development 
of the above hypothetical value sets in Germany and Denmark [56,57].  
3.7.2. VISUAL ANALOGUE SCALE VALUE SETS   
Two of the four VAS value sets in Study II, the Swedish and German EQ-5D-3L value sets, 
were developed using an experience-based perspective in the valuation studies [27,32]. The 
value sets from Denmark and the UK were developed using hypothetical perspectives [41]. 
The Swedish VAS value set was developed using data from the same survey used to develop 
the TTO value set involving respondents from the general population in 2004 and 2006 [27]. 
The German experience-based VAS value set was developed based on data from general 
population surveys in 2006 and 2007 with roughly 2,000 participants [32]. The Danish VAS 
value set was developed using a study conducted among the general population in Denmark 
in 1999 to 2000. The total number of participants in the valuation was 1,179 [41]. The VAS 
value set from the UK was developed in the same study in which the TTO value set was 
developed. The study was conducted in 1993, covering a total of 45 health states, with each 
participant valuing 15 health states [41].  
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3.8. DATA ANALYSIS  
In the thesis, a number statistical analyses were performed, including proportion of problems 
reported on the EQ-5D-3L dimensions; mean and median values with standard deviation 
(SD) and interquartile range (IQR) respectively; as well as ordinary least squares regressions 
(OLS) and prediction error measures.  
3.8.1. PARETIAN CLASSIFICATION OF HEALTH CHANGE  
In Study I, Paretian Classification of Health Change (PCHC), which employs the Pareto 
principle, was used to assess the longitudinal change in HRQoL as reported in the five 
dimensions of the EQ-5D questionnaire. Accordingly, four to five categories of PCHC are 
used to characterize longitudinal change in the EQ-5D dimensions [59,60]. A change is 
categorized as improved when at least one of the dimensions improves without any other 
worsening. In contrast, a change could be categorized as worsened when at least one of the 
dimensions worsens without any other showing improvement. When there is a mix of 
improvements and worsening across the dimensions, it is categorized as mixed. When there is 
no change in any of the five dimensions, the categorization, no change, is used. A fifth group, 
no problem categorizes a health state which shows no problems at both time points (i.e. 
health state 11111 at both time points) [59,60].  
PCHC provides a way to show, in a simple and clear manner, the overall change in health 
state related to specific interventions. In studies on the UK National Health Services PRO 
measures program, differences in the improved group after surgical interventions, such as hip 
and knee arthroplasties, were shown as compared to other interventions, such as hernia and 
cataract surgeries [60]. However, there are disadvantages to PCHC in relation to the fact that 
the magnitude of change is not taken into account. In addition, if the proportion of changes 
categorized as mixed dominates, the benefit of using PCHC is reduced [59,60].  
3.8.2. EQ VAS SCORE 
In Study I, analysis of covariance (ANCOVA) was performed to compare the outcome 
variable EQ VAS score across categorical variable sex controlled for age. Accordingly, EQ 
VAS scores were compared between men and women, controlling for age among patients in 
each register at baseline, at 1-year follow-up, and the change in EQ VAS score, as well as 
among the general population. ANCOVA allows accounting for a third variable, called 
covariates, when assessing a relationship between an independent and a dependent variable. 
To do this, ANCOVA controls the relationship between the covariate and the dependent 
variable statistically [61]. 
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In comparing how diagnoses across the different patient groups predict EQ VAS score, a 
two-level random intercept model was performed. In such models, regression analysis takes 
two levels into account in the model. The dependent variable (EQ VAS score) is clustered 
into different categories based on another variable (register). In such a random intercept 
model, the intercept is allowed to vary across the categories of the variable [62]. In Study I, a 
two-level random intercept model was used in comparing the predictive effect of different 
diagnoses on EQ VAS score, the outcome variable, across the registers. This helped to 
account for the difference in EQ VAS score across the diagnoses, categorized by register. The 
model takes the difference across registers into account as one level.   
3.8.3. BASELINE CHARACTERISTICS OF PARTICIPANTS (STUDY II)   
In Study II, Cochran-Armitage test was employed with the aim of assessing the uniformity of 
distribution of categorical demographic and clinical characteristics of patients in the SHAR 
across ASA classes at baseline. The Cochran-Armitage test is useful in assessing linear trends 
in two-way tables between a binary variable and an ordinal variable [63,64]. The Kendall 
rank correlation test was used to assess the uniformity of the distribution of the proportion of 
patients, in two ordinal variables (demographic/clinical characteristic with ASA class) are 
compared. This test is used in assessing the relationship between two ordinal variables [65]. 
Effect sizes for the statistical tests - Cochran-Armitage and Kendall rank correlation test - 
were determined by calculating the values for Cramer’s V and Kendall tau, respectively. 
Cramer’s V is useful in providing the magnitude of two-by-two chi-square tests, adding more 
information than just statistical significance found in the chi-square tests [66]. Similarly, the 
Kendall tau coefficient provides the magnitude of correlation for ordinal variables [65].  
3.8.4. ANALYSIS ON DISCRIMINATIVE ABILITY OF ASA CLASSES  
One-way analysis of variance (ANOVA) is used to compare mean values of a continuous 
variable across two or more groups, assessing statistical significance of the difference [67]. In 
Study II, one-way ANOVA was employed to assess the discriminative abilities of the 
different EQ-5D-3L value sets across ASA classes. In addition, the Kruskal Wallis test was 
conducted to confirm whether the one-way ANOVA was robust, as the assumption of 
homogeneity of variance was violated. The effect size measures for the tests one-way 
ANOVA test was performed using eta squared [68]. The Kruskal Wallis test provides an 
important alternative in comparing the mean value of an outcome variable across several 
groups, when the distribution is non-normal or unknown [69].  
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3.8.5. PREDICTIVE ABILITY OF ASA CLASSES ON HRQOL  
In Study II, ordinary least squares (OLS) models were employed in the assessment of the 
predictive ability of ASA classes on HRQoL of patients in the SHAR, as described by the 
different EQ-5D-3L value sets. Owing to the presence of heteroscedasticity, robust standard 
error (RSE) (heteroscedasticity-consistent) was used instead of standard error. RSE is useful 
in remedying the problems of violation of the assumption of equal variance [70]. Both 
unadjusted models and those adjusted for demographic, clinical and PROs were performed. 
In the assessment of prediction error, mean absolute error (MAE) and root mean square error 
(RMSE) were employed, compared across EQ-5D-3L value sets. MAE describes the mean of 
the difference between predicted and observed values in the regression model [71]. Root 
mean square error is the square root of the mean of squared error between observed and 
predicted values [72]. To take account of the variation in the interval of the different EQ-5D-
3L value sets, normalized versions of MAE and RMSE were also calculated.  
3.9. ETHICAL CONSIDERATIONS  
Study I was approved by the Regional Ethics Review Board in Gothenburg (# 1185-18/2019-
00812 and # 2020-04369) for the data retrieved from the NQRs and by the Swedish Ethical 
Authority (# 2020-03090) for the data from the general Swedish population survey. Study II 
was approved by the Regional Ethics Review Board in Gothenburg (# 271–14). The general 
population data are based on information from individuals who agreed to participate after 
having been informed about the study. The ethical review committees assessing the 
applications for the studies in the thesis, based on data from NQRs, waived the need for 
informed consent by individual patients whose data were used in the study, considering the 
issues of studies on NQRs discussed below.  
In the present thesis, informed consent is among the ethical issues relevant to the studies, 
owing to the use of data from many NQRs. Informed consent from participants in studies is 
an important component in the conduct of ethically sound research. According to the 
Declaration of Helsinki, researchers are required to seek the consent of research participants, 
after first providing them with sufficient comprehensible information. The information should 
address the benefits and risks associated with participation in the research [73].  
In the present thesis, as regards the data retrieved from registers in Study I and Study II, it 
was impractical to secure informed consent from each individual for which data were used. A 
number of challenges related to seeking informed consent in register-based research have 
been discussed [74]. The large sample size of the data from the registers is one of the reasons 
which made it both difficult and costly to seek consent from individuals. Another reason 
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relates to the possibility that the participation of individuals in the research might be reduced 
considerably after seeking informed consent from each patient. As data collected over several 
years are retrieved from registers, there is a possibility that patients may have already passed 
away, making it impossible to get informed consent [74].  
In mitigating the problem of not securing informed consent for the data from registers, it is 
important that patients are informed about the possibility of their data being used for research 
purposes when they are registered in NQRs. At this stage, patients are also informed that they 
can opt out of the registers at any time and have their records deleted, according to the 
Swedish Patient Data Act [75].  
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4. RESULTS 
4.1. HRQOL OF PATIENTS IN 11 NQRS (STUDY I) 
In most of the registers, the highest proportions of problems were reported in the 
pain/discomfort dimension at baseline and at 1-year follow-up, and in the general population, 
with the exception of patients with respiratory failure. The highest proportions of severe 
problems were also reported in the pain/discomfort dimension. A similar pattern in problems 
reported was also shown across the EQ-5D-3L dimensions for the different diagnoses within 
the registers.  
PCHC, which shows the pattern of changes in patients’ health states across time, showed the 
highest proportions of improved category recorded among patients with diagnoses in the 
intervention-based registers. These include patients in the ankle, hip, knee, and spine 
registers. The exceptions were patients in the respiratory and heart failure as well as fracture 
(where baseline data are collected with a recall of the time before injury) registers.  
Over the 1-year follow-up, improvements in EQ VAS score were recorded in almost all the 
registers, with the exception of patients with respiratory failure and those with fractures. In 
most registers - with the exception of fracture and respiratory failure patients at baseline, as 
well as BOA, fracture, heart failure, and respiratory failure patients at 1-year follow-up - 
women had lower mean EQ VAS scores, controlling for age based on ANCOVA tests. A 
similar pattern was observed by diagnosis at both time points. Mean EQ VAS scores by 
diagnosis at baseline, at 1-year follow-up, and the change over the period, had similar 
patterns as shown in the registers. Overall, mean EQ VAS scores were closer within a register 
than across registers. 
On the basis of the results of a two-level random intercept model, patients with diagnoses in 
almost all registers showed lower EQ VAS scores at baseline in comparison with the general 
population, with the exception of those in the fracture register. Similarly, diagnoses in most 
registers remained at lower EQ VAS scores than the general population at 1-year follow-up. 
Mean EQ VAS score in the different PCHC categories showed an increase over the follow-up 
period for those in the improved group, and a decrement in the worsened group. Furthermore, 
mean EQ VAS scores in nine selected health states were consistent with the severity of the 
health states both at baseline and 1-year follow-up.  
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4.2. PREDICTIVE ABILITY OF ASA CLASSES ON HRQOL (STUDY II) 
At both baseline and 1-year follow-up, the highest proportion of any problems, as well as 
severe problems, were reported in the pain/discomfort dimension. A similar pattern of 
reported problems was also shown across ASA classes. Mean EQ VAS score among SHAR 
patients showed improvement, from 56.0 at baseline to 76.7 at 1-year follow-up. The mean 
and median EQ VAS scores in the different ASA classes showed lower EQ VAS scores in 
higher ASA classes.  
Indicating the discriminative abilities of the different value sets, mean EQ-5D-3L indices, 
calculated based on the value sets, differed across ASA classes. The highest indices were 
found in ASA class I, decreasing over the classes, with the lowest found in ASA Class IV. 
This was shown to be statistically significant at both baseline and 1-year follow-up. The EQ-
5D-3L index based on the Swedish TTO showed the highest indices at baseline and at 1-year 
follow-up, with indices comparable to the Swedish TTO shown by the other value sets at 1-
year follow-up.  
In assessing the predictive effect of ASA classes on HRQoL, at baseline and at 1-year follow-
up, OLS models of all EQ-5D-3L indices based on all value sets and EQ VAS scores showed 
that ASA class predicts HRQoL regardless of the value set employed to calculate them. Both 
at baseline and 1-year follow-up, decrements associated with ASA classes were consistent. 
Larger decrements were found in the higher ASA classes. The pattern was similar, both in 
unadjusted models and models adjusted for age group, sex, BMI, laterality, Charnley class, 
and hip pain levels.  
The R2 values, indicating the amount of variation in HRQoL explained by ASA class 
membership, rose from 1-2% at baseline to 4-5% at 1-year follow-up. The prediction error 
measures, MAE and RMSE, and the normalized versions of the measures showed small 
variations across the different OLS models. Overall, the findings at 6-year follow-up were 
generally comparable to those at 1-year follow-up. 
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5. DISCUSSION 
The two studies demonstrated the usefulness of the EQ-5D-3L instrument in reflecting the 
view of patients on their overall health through reporting their HRQoL. In Study I, the EQ-
5D-3L has been used to compare the HRQoL of patients across 11 NQRs. Similarly, in Study 
II, the EQ-5D-3L has been used to show how the clinical status of patients predicts their 
HRQoL, through assessing the relationship between ASA classes and HRQoL of patients in 
the SHAR. In doing this, a comparison of the discriminative abilities of the different EQ-5D-
3L value sets across ASA classes was performed, thereby assessing the implication of which 
value set is used in calculating the EQ-5D-3L indices.  
5.1. MAIN FINDINGS AND COMPARISON TO OTHER STUDIES  
5.1.1. HRQOL OF PATIENTS IN 11 NQRS (STUDY I) 
The proportion of problems reported in the pain/discomfort dimension, highest among 
patients and in the general population, corresponded to pain symptom experienced in 
different patient groups. Accordingly, larger proportions were reported among patients in the 
intervention-based registers, which include spine, hip and knee registers where pain 
symptoms occur in the diseases [76–79]. The proportion of problems reported in the different 
registers could also be related to the types of symptoms of the diseases in the different 
registers. This could be exemplified by the lower proportion of problems in the 
pain/discomfort and mobility dimensions in the psoriasis register as compared to patients in 
the spine register, owing to the difference in the symptoms and disease conditions. This 
showed an expected difference in line with the difference in the nature of the diseases and 
how this affects the pertinent EQ-5D-3L dimensions.  
From baseline to 1-year follow-up, the problems reported reduced in most registers, with the 
greatest improvement found among patients in the intervention-based registers, including 
spine, hip, and knee. Similarly, PCHC categories across different diagnoses demonstrated a 
similar pattern with a higher proportion in the improved group among patients with diagnoses 
in many of the intervention-based registers. PCHC was used as important information, to 
show the change in the pattern of problems reported over time, in studies of diseases, such as 
heart failure, prostate cancer, diabetes mellitus, and overactive bladder [80–84]. The change 
in the problems reported in the different dimensions and PCHC categories followed the 
characteristics of diseases and the respective interventions made.     
EQ VAS provides information on a respondent’s view of their own overall health. In this 
study, mean EQ VAS score showed improvement over the period up to the one-year follow-
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up among patients across most of the registers. Among the exceptions were patients in the 
fracture register, which relates to the data collection approach in which HRQoL status prior to 
the occurrence of the fracture was reported for baseline using recall technique. The 
improvement in mean EQ VAS score seemed to be in line with improvements following 
interventions at baseline. Mean EQ VAS scores among patients in most registers, at both time 
points, were lower than in the general population [27]. The improvement in EQ VAS scores 
reflected the expected change from baseline to 1-year follow-up while remaining lower than 
the relatively healthier general population.    
Mean EQ VAS scores also showed consistent pattern to the problems reported on the EQ-5D-
3L dimensions, with lower mean EQ VAS scores among patients who reported higher 
proportions of problems. The change in mean EQ VAS score was shown to be consistent 
with changes in problems reported on the EQ-5D-3L dimensions as well. This is in line with 
previous studies demonstrating such consistency [85,86]. The pattern of consistency between 
the EQ-5D-3L dimensions and EQ VAS scores was similar across PCHC categories. Mean 
EQ VAS scores of selected health states showed similar consistency with the severity of the 
health states. A similar pattern was reported in another study, in which mean EQ VAS scores 
were in line with the severity of health states [87]. Another study of patients with Parkinson’s 
disease showed the importance of the EQ-5D-3L dimensions and the EQ VAS in 
documenting the HRQoL of patients and assessing the severity of diseases [88].  
5.1.2. PREDICTIVE ABILITY OF ASA CLASSES ON HRQOL (STUDY II) 
The fact that the highest proportion of problems are reported in the pain/discomfort 
dimension demonstrate that pain is an important symptom among patients with osteoarthritis 
of the hip [89]. This is particularly the case at baseline and remains so to a greater extent at 1-
year follow-up relative to problems in other dimensions. The study showed that EQ-5D-3L 
indices calculated based on all the EQ-5D-3L values sets and on the patient-reported EQ 
VAS score differentiated among the ASA classes. Among the value sets, Swedish TTO had 
higher EQ-5D-3L indices in all ASA classes than in the other value sets at baseline. At 1-year 
follow-up the difference decreased, which could be due to the difference between the 
Swedish experience-based TTO value set and the hypothetical German, Danish, and UK TTO 
value sets [41,56–58]. The difference could be attributed to the fact that in the hypothetical 
value sets, much lower indices are assigned to severe health states than in the Swedish TTO; 
however, healthier states are valued much closer to the Swedish TTO. Despite variation in the 
indices resulting from the different value sets, discriminative abilities of ASA class remains 
demonstrated in all of them.  
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EQ-5D-3L indices based on all value sets and on patient reported EQ VAS score showed the 
predictive effect of ASA classes on HRQoL. This demonstrated that ASA class influences 
HRQoL both at baseline and even to a higher extent postoperatively. A similar finding was 
reported in a study which assessed a relationship between ASA class and functional recovery 
following surgery for hip fracture [90]. Higher decrements in HRQoL among more severe 
ASA classes were also shown in yet another study on surgical interventions for hip fracture 
[91]. In the comparison of the different value sets, decrements in HRQoL across ASA classes 
were the greatest among the hypothetical TTO value sets at baseline. At 1-year follow-up, the 
highest decrements were in the Danish VAS and the value sets from the UK. The difference 
could be attributed to the wider interval in the EQ-5D-3L index of the hypothetical value sets.  
The R2 of all the regression models of the different value sets showed improvement from 
baseline to 1-year follow-up, explaining more variation by membership to ASA classes. 
Larger R2 values are shown in the patient-reported EQ VAS score and VAS value sets, which 
could be due to the VAS method of valuation study. In terms of the prediction error, the 
Swedish TTO had the lowest MAE and RMSE at both time points, while normalized MAE 
and RMSE were lowest among Danish VAS at baseline and Danish TTO at 1-year follow-up.  
The findings of the study regarding the comparison of value sets in relation to discriminative 
and predictive abilities of ASA classes HRQoL showed varying indices and error measures. 
However, both the discriminative and predictive abilities of ASA were demonstrated across 
the value sets. So, the findings do not indicate to a suggestion of a particular value set but 
showed that an understanding of features of value sets used to calculate HRQoL is important.    
5.2. STRENGTHS AND LIMITATIONS 
In this thesis there are a number of strengths in relation to the data sets and methods 
employed. One of the important strengths of the studies concerns the large size of patient 
records in the registers and from the general population. This contributed to addressing the 
research questions in each study with increased power. Another strength of the thesis is 
related to the comprehensive study across many patient groups in Study I. This has 
contributed to the literature by documenting HRQoL in several patient groups at once. 
Another strength of the thesis is that a longitudinal study design was employed in both 
studies. In comparison to cross-sectional studies, longitudinal ones provides an advantage of 
assessing change over time through measurements taken at repeated follow-ups [92]. 
Accordingly, in this thesis, longitudinal design helped in showing HRQoL status at baseline 
and follow-up stages, as well as the changes over the follow-up period.  
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The studies also have a number of limitations that should be taken into consideration when 
interpreting the findings. Variations in the mode of data collection on PROs across the NQRs, 
and over time, constitute a limitation which could lead to differences in HRQoL measures. 
The inclusion of only patient records with complete data both at baseline and 1-year follow-
up in both studies which excludes patients with only baseline or 1-year follow-up data is 
another limitation. This could potentially lead to bias with a possible variation in the 
measurement of HRQoL between the groups included and those not included. However, 
analysis of this in Study I showed that findings concerning patients with data only at baseline 
or at 1-year follow-up only are comparable to those with complete baseline and 1-year 
follow-up data. Another limitation relates to the time difference in the time of the studies 
which developed the value sets compared in Study II. The time of data collection for the 
value sets development studies ranged from the 1990s to 2000s. This could contribute to 
differences in valuations which are unaccounted for in the study. The use of different 
regression models in the development of the value sets that were compared could also lead to 
differences in the indices which was not assessed in this study. Such variation due to 
modeling has been reported in a study comparing different value sets [93].   
5.3. LESSONS LEARNED  
Several important lessons are learned from the thesis regarding the EQ-5D-3L questionnaire 
and the value sets used to summarize such data into a single index. One is the importance of 
the EQ-5D-3L questionnaire in providing complementary information to the clinical data by 
adding the views of patients on their health status. Another lesson concerns the consistency 
between problems reported on the EQ-5D-3L dimensions and the EQ VAS components, as 
demonstrated in the different patient groups. This highlights the importance of the often 
underused EQ VAS component.  
Yet another important lesson is that the thesis demonstrated that it is crucial to have a clear 
understanding of the value sets employed to calculate EQ-5D-3L indices. This is because 
several features such as valuation methods employed, perspectives taken, the setting in which 
the value set was developed, as well as others factors such as modeling approaches need to be 
considered. This is important as choice of value sets might have implications on indices 
calculated which could be used to inform resource allocation decisions through economic 
evaluations.  
Furthermore, the thesis can exemplify the way in which data sets from the Swedish NQRs, 
which hold a wealth of information on different patient groups, could be used in a manner 
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that adds evidence to the literature in several areas. The collaboration across several registers 
in conducting a large study demonstrated in the present thesis also indicates to the potential of 
producing research outputs that could provide useful inputs for practical applications.  
5.4. IMPLICATIONS OF THE THESIS  
The information from the two studies in the present thesis demonstrate the importance of the 
EQ-5D-3L questionnaire in documenting the HRQoL of patients, as well as approaches for 
summarizing and presenting HRQoL data. Among the specific implications of the findings in 
Study I in the provision of crucial information by documenting data on the HRQoL of several 
patient groups and diagnoses within the registers, using large data sets collected alongside 
routine clinical practice. This could be helpful in improving the care provided to patients, by 
using HRQoL data together with clinical data.  
The study also demonstrated the consistency between the EQ-5D-3L dimensions and EQ 
VAS scores with proportions of problems reported going in line with mean EQ VAS scores. 
In relation to this, the study added to the evidence that EQ VAS score is an important 
measure of self-reported health. This is demonstrated by its consistency with the EQ-5D-3L 
descriptive system, as well as the nature of diagnoses and patient groups. Thus, the EQ VAS 
score reflects patients’ health status, which reinforces the use of EQ VAS to compare HRQoL 
within and between patient groups. Accordingly, there is a need for further investigation into 
EQ VAS in reporting HRQoL and as a basis to explore patient value sets. This will give 
insight on exploration of potential value sets through experience-based perspectives. Such 
studies could contribute to discussions of public health importance on approaches to health 
care resource allocation.    
Study II addressed the aspect of choice of approach in summarizing the data on the EQ-5D-
3L descriptive system using value sets and how the choice affects the resulting HRQoL 
measurement. Accordingly, the study’s findings provided information on how the use of 
different EQ-5D-3L value sets impacts the measurement of HRQoL in showing the 
discriminative abilities of ASA classes. In relation to this, the study demonstrated the 
predictive ability of ASA classes on HRQoL, adding useful information for clinical practice 
which could help in determining care required for groups of patients in different ASA classes. 
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6. CONCLUSIONS 
In this thesis, the importance of the EQ-5D-3L instrument in measuring the HRQoL of 
patients to provide the perspective of patients on their health as an addition to objective 
clinical data. Study I documented comprehensive information on the HRQoL of patients in 
the 11 NQRs, with comparisons made with data from the general population. The fact that 
HRQoL reported across patient groups varied based on the symptoms manifested by the 
conditions was demonstrated in the study. In relation to this, the consistent relationship 
between problems reported on the EQ-5D-3L dimensions and EQ VAS scores was 
demonstrated across the different patient groups and in the general population.  
In Study II, the discriminative ability of all value sets investigated across ASA classes was 
demonstrated. Hence the HRQoL reported using each of the value sets showed lower values 
in more severe ASA classes and vice versa. In relation to this, the study also added to the 
evidence on the predictive ability of ASA classes on HRQoL at baseline as well as at follow-
ups. This was demonstrated in all the value sets employed to calculate EQ-5D-3L indices. 
The findings do not indicate to a specific value set among the compared ones but the 
importance of a clearer understanding of the value sets employed in calculating EQ-5D-3L 
index as it can be affected by the different features of the value set.  
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7. SUGGESTIONS FOR FUTURE RESEARCH 
This thesis investigated the HRQoL of different patient groups and compared value sets 
employed to summarize such HRQoL data. Evidence from such large studies is not 
commonly available in the literature. Therefore, future research should focus on more such 
studies, especially regarding documenting HRQoL of different patient groups in various 
settings using the EQ-5D instrument in its different versions. This will help document 
HRQoL of a wide range of patient groups to understand the views of patients on their health. 
The consistency of EQ VAS scores with the problems reported in the EQ-5D-3L dimensions 
was demonstrated in the thesis. This indicates the importance of exploring the relationship 
between the EQ-5D-3L dimensions and EQ VAS score to assess their potential for 
developing patient VAS value sets. This will add to the literature on experience-based value 
sets based on patient HRQoL data. Based on findings from such studies the potential of 
experience-based value sets to be applied for decision making could be explored.  
In terms of comparing the implications of using different value sets on the resulting EQ-5D-
3L indices, studies comparing more value sets and using other patient groups would provide a 
fuller picture of differences across value sets. Evidence from such studies will be useful in 
making informed choice when using EQ-5D-3L value sets. 
Conducting the above suggested studies on HRQoL data collected using the five-level 
version of the EQ-5D questionnaire would be useful to document differences from the three-
level version. In addition, owing to the increased use of the EQ-5D-5L questionnaire, 
evidence from studies on this version will provide important information on the 
characteristics of value sets and the potential of patient value sets.
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